Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein

Journal of Clinical Pharmacology

Volumn 55, Issue 1, 2015, Pages 56-62

  Robertson, Sarah M ^a   Luo, Xia ^a   Dubey, Neeraj ^a   Li, Chonghua ^a   Chavan, Ajit B ^a   Gilmartin, Geoffrey S ^a   Higgins, Mark ^a   Mahnke, Lisa ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

Cytochrome P450; Drug interactions; Ivacaftor; P glycoprotein

Indexed keywords

1 HYDROXYMIDAZOLAM; 2 HYDROXYDESIPRAMINE; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DESIPRAMINE; DIGOXIN; DRUG METABOLITE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; IVACAFTOR; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; NORETHISTERONE; PLACEBO; ROSIGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINOPHENOL DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 3A INHIBITOR; FOLLITROPIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; QUINOLONE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADULT; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; DYSMENORRHEA; FEMALE; HEADACHE; HUMAN; KIDNEY CLEARANCE; LETHARGY; LIVER FUNCTION TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NORMAL HUMAN; ORAL CLEARANCE; PHARYNGITIS; PLASMA CONCENTRATION-TIME CURVE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; VOMITING; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG INTERACTION; GENETICS; METABOLISM; MIDDLE AGED; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AMINOPHENOLS; CONTRACEPTIVES, ORAL, COMBINED; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DESIPRAMINE; DIGOXIN; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MALE; MIDAZOLAM; MIDDLE AGED; NORETHINDRONE; P-GLYCOPROTEIN; PROGESTERONE; QUINOLONES; THIAZOLIDINEDIONES; YOUNG ADULT;

EID: 84919770501     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.377     Document Type: Article

References (12)

1. Boucher RC, et al. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med. 2007; 13: 231-241.
2. Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012; 11: 237-245.
3. Kalydeco®, (ivacaftor) Tablets, Prescribing Information [package insert]. Boston, MA: Vertex Pharmaceuticals Inc; 2014.
4. Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, February 2012. US Food and Drug Administration. 2012.
5. Stanczyk FZ, Archer DF, Bhavnani BR,. Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception. 2013; 87: 706-727.
6. Butler K, Teng R,. Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers. Curr Med Res Opin. 2011; 27: 1585-1593.
7. Friedrich C, Port A, Ring A, et al. Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: An open-label, two-period, fixed-sequence, multiple-dose study. Clin Drug Investig. 2011; 31: 643-653.
8. Korhonen T, Turpeinen M, Tolonen A, Laine K, Pelkonen O,. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008; 110: 56-66.
9. Stanczyk FZ, Roy S,. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception. 1990; 42: 67-96.
10. Andrews E, Damle BE, Fang A, et al. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. Br J Clin Pharmacol. 2008; 65: 531-539.
11. Garg V, van Heeswijk R, Yang Y, Kauffman R, Smith F, Adda N,. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir. J Clin Pharmacol. 2012; 52: 1574-1583.
12. Emend®, (aprepitant) Capsules, Prescribing Information [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2013.